Expertise in
12
conditions

Dr. Scott Sonnier

Hematology Oncology
2820 Napoleon Ave, 
New Orleans, LA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
12
conditions
2820 Napoleon Ave, 
New Orleans, LA 

Overview

Scott Sonnier is a Hematologist Oncology provider practicing medicine in New Orleans, Louisiana.

Dr. Sonnier is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Intraductal Papilloma, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration.

Dr. Sonnier is board certified in American Board Of Internal Medicine - Hematology/Oncology. He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 4 clinical trials. Dr. Sonnier is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in LA

Board Certifications

American Board Of Internal Medicine - Hematology/Oncology

Hospital Affiliations

St Bernard Parish Hospital
Ochsner Medical Center Acute
Touro Infirmary
Ochsner Medical Center-Kenner
Ochsner Medical Center - Baton Rouge

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ochsner Health Center - Baptist Napoleon Medical Plaza
2820 Napoleon Ave, New Orleans, LA 70115
Other Locations
The Gayle and Tom Benson Cancer Center
1514 Jefferson Highway, New Orleans, LA 70121
Ochsner Medical Complex - The Grove
10310 The Grove Blvd, Baton Rouge, LA 70836
Ochsner Cancer Center - Baton Rouge
17050 Medical Center Drive, Baton Rouge, LA 70816

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
View 3 Less Clinical Trials

1 Total Publications

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: June 26, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Laura E. Finn
Hematology Oncology
Expertise in
25
conditions
Dr. Laura E. Finn
Hematology Oncology
Referral may be required
Before you request

The Gayle And Tom Benson Cancer Center

1514 Jefferson Highway, 
New Orleans, LA 
 (60.8 miles away)
504-842-3910
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Finn is a Hematologist Oncology provider practicing medicine in New Orleans, Louisiana. Dr. Finn is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Finn is board certified in American Board Of Internal Medicine - Hematology/Oncology. Dr. Finn is currently accepting new patients.

Expertise in
13
conditions
Dr. Chris G. Theodossiou
Hematology Oncology
Expertise in
13
conditions
Dr. Chris G. Theodossiou
Hematology Oncology
Referral may be required
Before you request

Ochsner Medical Center - New Orleans

1514 Jefferson Highway, 
New Orleans, LA 
 (60.8 miles away)
504-842-3910
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Chris Theodossiou is a Hematologist Oncology provider practicing medicine in New Orleans, Louisiana. Dr. Theodossiou is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Bone Marrow Aspiration, and Endoscopy. Dr. Theodossiou is board certified in American Board Of Internal Medicine - Hematology/Oncology. Dr. Theodossiou is currently accepting new patients.

Expertise in
15
conditions
Dr. Ashley D. Staton
Hematology Oncology
Expertise in
15
conditions
Dr. Ashley D. Staton
Hematology Oncology
Referral may be required
Before you request

The Gayle And Tom Benson Cancer Center

1514 Jefferson Hwy, 
New Orleans, LA 
 (60.8 miles away)
866-624-7637
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ashley Staton is a Hematologist Oncology provider practicing medicine in New Orleans, Louisiana. Dr. Staton is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Staton is board certified in American Board Of Internal Medicine - Hematology/Oncology. Dr. Staton is currently accepting new patients.

Frequently Asked Questions about Dr. Scott Sonnier

How do I make an appointment with Dr. Scott Sonnier?

You can book an appointment with Dr. Scott Sonnier by calling their office at 504-842-3990. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott Sonnier a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott Sonnier is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott Sonnier specialize in?

While Dr. Scott Sonnier is a Hematology Oncology, they have specific expertise in Paget Disease of the Breast, Intraductal Papilloma, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Scott Sonnier participate in research or clinical trials?

Yes. Dr. Scott Sonnier has published 1 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Scott Sonnier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott Sonnier accept my insurance?

Dr. Scott Sonnier accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 504-842-3990 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sonnier's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 102 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile